Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $160

robot
Abstract generation in progress

Bernstein has reiterated its Buy rating on Gilead Sciences (GILD.US) and increased its target price to $160. This adjustment likely reflects a positive outlook on the company’s financial performance or product pipeline from the analyst firm.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin